Fed Circ rejects Sanofi’s bid to resurrect Lantus patents

04-01-2022

Alex Baldwin

Fed Circ rejects Sanofi’s bid to resurrect Lantus patents

HJBC / Shutterstock.com

The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.


US Court of Appeals for the Federal Circuit, Lantus SoloStar, insulin, IPR, PTAB, medical devices

LSIPR